Drug toxicoderma: possible causes, clinical manifestations and approaches to management at the outpatient’s stage
https://doi.org/10.30629/0023-2149-2020-98-11-12-745-751
Abstract
Adverse cutaneous drug reactions are skin manifestations resulting from systemic drug administration. Toxicoderma under medication treatment is the most common adverse cutaneous reaction with difficulty to diagnose, especially at early stages. The development and active introduction of new drugs into practice, uncontrolled self-medication of patients, polypharmacy, and repeated contact with one and the same preparation, contribute to the growth of toxicoderma. Doctors should treat patients with toxicoderma carefully, as it can be developed at any time and have different clinical manifestations. The pathogenesis of toxicoderma is not fully understood, which limits the possibility of the diagnosis, treatment and prevention. The benefit/risk ratio evaluation of prescribing medications is the basis of pharmacological safety and doctors, especially of primary health care (general practitioners), should always put it into practice.
About the Authors
V. N. Larina
Pirogov Russian National Research Medical University of the Ministry of Health of Russia
Russian Federation
Russian Federation
Vera N. Larina — MD, PhD, DSc, Head of the Department of Polyclinic Therapy of the Faculty of Medicine
117997, Moscow
T. A. Gaydina
Pirogov Russian National Research Medical University of the Ministry of Health of Russia
Russian Federation
Russian Federation
117997, Moscow
A. S. Dvornikov
Pirogov Russian National Research Medical University of the Ministry of Health of Russia
Russian Federation
Russian Federation
117997, Moscow
K. E. Nazimkin
Pirogov Russian National Research Medical University of the Ministry of Health of Russia
Russian Federation
Russian Federation
117997, Moscow
References
1. Formica D., Sultana J., Cutroneo P.M., Lucchesi S., Angelica R., Crisafulli S., Ingrasciotta Y., Salvo F., Spina E., Trifirò G. The economic burden of preventable adverse drug reactions: a systematic review of observational studies. Expert Opin. Drug. Saf. 2018;17(7):681–695. DOI: 10.1080/14740338.2018.1491547
2. Aung A., Tang M., Adler N., de Menezes S.L., Goh M.S.Y., Tee H.W., Trubiano J.A., Puy R., Zubrinich C.M., Graudins L.V. Adverse Drug Reactions Reported by Healthcare Professionals: Reaction Characteristics and Time to Reporting. J. Clin. Pharmacol. 2018;58(10):1332–1339. DOI: 10.1002/jcph.1148
3. Vykhrystsenko L, Velichansky O, Sidorenko E, Zakharova O. The Stevens–Johnson syndrome and toxic epidermal necrolysis in patients of Vitebsk regional clinical hospital: a retrospective analysis. Immunopathology, Allergology, Infectology. 2017;4:21–30. (in Russian) DOI: 10.14427/jipai.2017.4.21
4. Niebel D., Wenzel J. Immunpathologie von kutanen Medikamentennebenwirkungen. Pathologe. 2018;39(6):563–570. DOI:10.1007/s00292-018-0487-x
5. Graudins L, Trubiano J., Zubrinich C., Elliott A., Aung A. Medication-related anaphylaxis treated in hospital: Agents implicated, patient outcomes, and management lessons. Pharmacoepidemiol. Drug. Saf. 2018;27(9):1029–1033. DOI: 10.1002/pds.4587
6. Kubanova A, Samtsov A, Zaslavsky D. The roots of international dermatology. Vestnik dermatologii i venerologii. 2011;87(3):162–173. DOI: 0.25208/vdv1049 (in Russian)
7. Toksidermiya. Klinicheskie rekomendatsii MZ RF. 2016. URL: http://kokb45.ru/wp-content/ uploads/2018/06/Toksidermiya.pdf (Accessed Dec 06, 2020). (in Russian)
8. Schneider J.A., Cohen P.R. Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures. Adv. Ther. 2017;34(6):1235–1244. DOI: 10.1007/s12325-017-0530-y
9. Dodiuk-Gad R.P., Chung W.H., Valeyrie-Allanore L., Shear N.H. Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: An Update. Am. J. Clin. Dermatol. 2015;16(6):475–93. DOI: 10.1007/s40257-015-0158-0
10. Letko E., Papaliodis D., Papaliodis G., Daoud Y., Ahmed A., Foster C. Stevens–Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Annals of Allergy, Asthma & Immunology. 2005;94(4):419–436. DOI: 10.1016/s1081-1206(10)61112-x
11. Goodman H. Nikolsky signpage from notable contributors to the knowledge of dermatology. AMA Arch. Derm. Syphilol. 1953;68(3):334. DOI: 10.1001/archderm.1953.01540090096013
12. Harr T., French L.E. Toxic epidermal necrolysis and Stevens– Johnson syndrome. Orphanet J. Rare Dis. 2010;16(5):39. DOI: 10.1186/1750-1172-5-39
13. Shegaonkar S.H. Bilateral panophthalmitis following toxic epidermal necrolysis: A case report. Indian J. Ophthalmol. 2020;68(3):538– 540. DOI: 10.4103/ijo.IJO_1208_19
14. Hasegawa A., Abe R. Recent advances in managing and understanding Stevens–Johnson syndrome and toxic epidermal necrolysis. F1000Res. 2020;16(9):F1000 Faculty Rev-612. DOI: 10.12688/f1000research.24748.1
15. Jun I., Rim J.H., Kim M.K., Yoon K.C., Joo C.K., Kinoshita S., Seo K.Y., Ueta M. Association of human antigen class I genes with cold medicine-related Stevens–Johnson syndrome with severe ocular complications in a Korean population. Br. J. Ophthalmol. 2019;103(4):573–576. DOI: 10.1136/bjophthalmol-2018-313263
16. Nicoletti P., Barrett S., McEvoy L., Daly A.K., Aithal G., Lucena M.I., Andrade R.J., Wadelius M., Hallberg P., Stephens C., Bjornsson E.S., Friedmann P., Kainu K., Laitinen T., Marson A., Molokhia M., Phillips E., Pichler W., Romano A., Shear N., Sills G., Tanno L.K., Swale A., Floratos A., Shen Y., Nelson M.R., Watkins P.B., Daly M.J., Morris A.P., Alfirevic A., Pirmohamed M. Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions. Clin Pharmacol. Ther. 2019;106(5):1028–1036. DOI: 10.1002/cpt.1493
17. Ke C.H., Chung W.H., Wen Y.H., Huang Y.B., Chuang H.Y., Tain Y.L., Wang Y.L., Wu C.C., Hsu C.N. Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions. J. Rheumatol. 2017;44(6):835– 843. DOI: 10.3899/jrheum.151476
18. Jutkowitz E., Dubreuil M., Lu N., Kuntz K.M., Choi H.K. The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States. Semin Arthritis Rheum. 2017;46(5):594–600. DOI: 10.1016/j.semarthrit.2016.10.009
19. Correia O., Delgado L., Ramos J., Resende C., Torrinha J. Cutaneous T-CellRecruitmentinToxicEpidermalNecrolysis:FurtherEvidenceof CD8+ Lymphocyte Involvement. Arch. Dermatol. 1993;129(4):466– 468. DOI: 10.1001/archderm.1993.01680250078010
20. Paul C., Wolkenstein P., Adle H., Wechsler J., Garchon H.J., Revuz J., Roujeau J.C. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Brit. J. Dermatology. 1996;134(4):710– 714. DOI: 10.1111/j.1365-2133.1996.tb06976.x
21. Viard I., Wehrli P., Bullani R., Schneider P., Holler N., Salomon D., Hunziker T., Saurat J.H., Tschopp J., French L.E. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;16;282(5388):490–3. DOI: 10.1126/science.282.5388.490
22. Nassif A., Bensussan A., Boumsell L., Deniaud A., Moslehi H., Wolkenstein P., Bagot M., Roujeau J.C. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J. Allergy Clin. Immunol. 2004;114(5):1209–15. DOI: 10.1016/j.jaci.2004.07.047
23. Wei C., Chung W., Huang H., Chen Y., Hung S. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens–Johnson syndrome. J. Allergy Clin. Immunol. 2012;129(6):1562–1569.e5. DOI: 10.1016/j.jaci.2011.12.990
24. Génin E, Schumacher M, Roujeau J., Naldi L., Liss Y., Kazma R., Sekula P., Hovnanian A., Mockenhaupt M. Genome-wide association study of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in Europe. Orphanet J. Rare Dis. 2011;6:52. DOI: 10.1186/1750-1172-6-52
25. Borchers A., Lee J., Naguwa S., Cheema G., Gershwin M. Stevens– Johnson syndrome and toxic epidermal necrolysis. Autoimmun. Rev. 2008;7(8):598–605. DOI: 10.1016/j.autrev.2008.06.004
26. Frey N., Jossi J., Bodmer M., Bircher A., Jick S.S., Meier C.R., Spoendlin J. The Epidemiology of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in the UK. J. Invest. Dermatol. 2017;137(6):1240–1247. DOI: 10.1016/j.jid.2017.01.031
27. Jang M.S., Lee J.Y., Kim J., Kim G.W., Kim B.K., Kim J.Y., Park H.W., Cho S.H., Min K.U., Kang H.R. Incidence of Stevens– Johnson Syndrome and Toxic Epidermal Necrolysis: A Nationwide Population-Based Study Using National Health Insurance Database in Korea. PLoS One. 201611;11(11):e0165933. DOI: 10.1371/journal.pone.0165933
28. Naegele D., Sekula P., Paulmann M., Mockenhaupt M. Incidence of Stevens–Johnson syndrom/toxic epidermal necrolysis: results of 10 years from the German registry. Pharmacoepidemiol. Drug. Saf. 2017;26:3
29. Hsu D., Brieva J., Silverberg N., Silverberg J. Morbidity and Mortality of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults. J. Invest. Dermatol. 2016;136(7):1387–1397. DOI: 10.1016/j.jid.2016.03.023
30. Micheletti R.G., Chiesa-Fuxench Z., Noe M.H., Stephen S., Aleshin M., Agarwal A., Boggs J., Cardones A.R., Chen J.K., Cotliar J., Davis M.D.P., Dominguez A., Fox L.P., Gordon S., Hamrick R., Ho B., Hughey L.C., Jones L.M., Kaffenberger B.H., Kindley K., Kroshinsky D., Kwong B.Y., Miller D.D., Mostaghimi A., Musiek A., Ortega-Loayza A.G., Patel R., Posligua A., Rani M., Saluja S., Sharon V.R., Shinkai K., John J.S., Strickland N., Summers E.M., Sun N., Wanat K.A., Wetter D.A., Worswick S., Yang C., Margolis D.J., Gelfand J.M., Rosenbach M. Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the United States. J. Invest. Dermatol. 2018;138(11):2315–2321. DOI: 10.1016/j.jid.2018.04.027
31. Teplyuk N.P., Kadyrova Z.S. Diversity of clinical manifestations of drug toxidermia in patients who were in the clinic of skin and sexually transmitted diseases named after V.A. Rakhmanova FGAOU at the First Moscow State Medical University named after I.M. Sechenov Ministry of Health of Russia. Modern problems of science and education. 2019;3. (in Russian). DOI: 10.17513/spno.28900
32. Sekula P., Dunant A., Mockenhaupt M., Naldi L., Bouwes Bavinck J.N., Halevy S., Kardaun S., Sidoroff A., Liss Y., Schumacher M., Roujeau J.C. RegiSCAR study group. Comprehensive survival analysis of a cohort of patients with Stevens–Johnson syndrome and toxic epidermal necrolysis. J. Invest. Dermatol. 2013;133(5):1197–204. DOI: 10.1038/jid.2012.510
33. Sindrom Stivensa–Dzhonsona. Klinicheskie rekomendatsii MZ RF. 2016. URL: https://www.cnikvi.ru/docs/clinic_recs/klinicheskie-rekomendatsii-2017/Синдром%20Стивенса–Джонсона.КР228.docx (Accessed March 30, 2020). (in Russian)
34. Abe R., Yoshioka N., Murata J., Fujita Y, Shimizu H. Granulysin as a marker for early diagnosis of the Stevens–Johnson syndrome. Ann. Intern. Med. 2009;151(7):514–515. DOI: 10.7326/0003-4819-151-7-200910060-00016
35. Hasegawa A., Shinkuma S., Hayashi R., Hama N., Watanabe H., Kinoshita M., Ogawa Y., Abe R. RIP3 as a diagnostic and severity marker for Stevens–Johnson syndrome and toxic epidermal necrolysis. J. Allergy Clin. Immunol. Pract. 2020;8(5):1768–1771.e7. DOI: 10.1016/j.jaip.2020.01.006
36. Tairova R.T., Gaydina T.A., Dvornikov A.S., Tazartukova A.D., Lyang O.V. Difficulties in differential diagnosis of cutaneous manifestations in patients with coronavirus infection. Bulletin of RSMU. 2020;(5):102–107. (in Russian). DOI: 10.24075/brsmu.2020.062
37. Zimmermann S., Sekula P., Venhoff M., Motschall E., Knaus J., Schumacher M., Mockenhaupt M. Systemic Immunomodulating Therapies for Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis:ASystematic Review and Meta-analysis. JAMA Dermatol. 2017;153(6):514–522. DOI: 10.1001/jamadermatol.2016.5668
38. Terblanche A., Meyer J., Godman B., Summers R. Impact of a pharmacistdriven pharmacovigilance system in a secondary hospital in the Gauteng Province of South Africa. Hosp. Pract. 2018;46(4):221–228. DOI: 10.1080/21548331.2018.1510708
39. Schmiedl S., Rottenkolber M., Szymanski J., Drewelow B., Siegmund W., Hippius M., Farker K., Guenther I.R., Hasford J., Thuermann P.A. German Net of Regional Pharmacovigilance Centers (NRPC). Preventable ADRs leading to hospitalization -results of a long-term prospective safety study with 6,427 ADR cases focusing on elderly patients. Expert Opin. Drug. Saf. 2018;17(2):125–137. DOI: 10.1080/14740338.2018.1415322
40. The Canadian Deprescribing Network. URL: https://www.deprescribingnetwork.ca/canadian-deprescribing-network (Accessed March 30, 2020)
Review
For citations:
Larina V.N., Gaydina T.A., Dvornikov A.S., Nazimkin K.E. Drug toxicoderma: possible causes, clinical manifestations and approaches to management at the outpatient’s stage. Clinical Medicine (Russian Journal). 2020;98(11-12):745-751. (In Russ.) https://doi.org/10.30629/0023-2149-2020-98-11-12-745-751
Views:
2726
Email this article 